Episodes
-
Prof. Giacomo Grasselli takes us through the new concepts and explains why defining ARDS is such a difficult proposition.
-
Episodes manquant?
-
Prof. Susanne Wegener discusses her team’s work to develop deep learning models that outperform neurologists in predicting patients’ clinical outcomes after stroke.
-
A conversation with Dr. Luis Paz-Ares about the key questions raised by the ADAURA trial of adjuvant osimertinib in early-stage NSCLC.
-
Drs Niels Holm and Lene Andreasen explore the latest data on OCT and discuss its potential as an effective approach in PCI.
-
Professor Andrew Beggs discusses best practice in the use of next-generational sequencing within thyroid and non-small cell lung cancers.
This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company -
Prof. Malin Parmar explains why stem cell therapy is such a good option for patients with Parkinson’s disease and how its safety is being tested in the STEM-PD trial.
-
Professors Morris Brown and Bryan Williams join Jane Godsland to explore the theories behind resistant hypertension, and the latest treatment approaches.
-
We speak to Dr. Elena Castro about the latest data on PARP inhibitors in prostate cancer as presented at this year's ASCO Genitourinary Cancers Symposium.
-
We talk to Dr. Nathalie van Havre and Dr. Elsbeth Headley about ongoing medical education in the digital age.
-
Dr. Jane Godsland & Dr. Erik Heintz discuss the vision for Springer Medicine and offer some teasers for what's to come.
